P3.17-13 SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) NSCLC — A Multicenter Single-Arm Phase II Trial
JOURNAL OF THORACIC ONCOLOGY（2018）
Key words
neoadjuvant immunotherapy,Stage IIIA,immune checkpoint inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined